diabetic macular edema
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: patients who were treated with intravitreal triamcinolone acetonide from April 1st, 2012 to October 31st, 2018.
Exclusion criteria
Exclusion criteria: patients who rejected a registration to this study patients who were assessed not suitable by principal or sub investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intra ocular pressure at preoperative, 1 week, 4 weeks, 12 weeks, and 24 weeks after the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| best corrective visual acuity and foveal thickness at preoperative, 1 week, 4 weeks, 12 weeks, and 24 weeks after the treatment. | — |
Countries
Japan
Contacts
Faculty of medical sciences, University of Fukui Department of Ophthalmology